IJMPR 2024, 8(4), 69-73

International Journal of Modern Pharmaceutical Research
www.ijmpronline.com

ISSN: 2319-5878
IJMPR
Research Article

SJIF Impact Factor: 6.669

# ANTI-DIABETIC BIOACTIVE TAILORED TRANSFERSOMES: AS A POTENTIAL CARRIER FOR ENHANCED TRANSDERMAL DELIVERY: FORMULATION DESIGN AND CHARACTERIZATION

**Rashmi Haldkar[1]* and Kriti Sood[2]**

[1]Sir Atma Ram Institute of Pharmacy and Technology, Saript, Khasra no 69/1, PHN 30, Tilwara-Nagpur Road, Manegaon, Jabalpur, MP, 482051.
[2]Guru Ramdas Khalsa Institute of Science and Technology, Kukri Kheda, Barela, Jabalpur, MP, 483001.

**Article Received on: 24/01/2024**
**Article Revised on: 15/02/2024**
**Article Accepted on: 05/03/2024**

***Corresponding Author**
**Rashmi Haldkar**
Sir Atma Ram Institute of Pharmacy and Technology, Saript, Khasra no 69/1, PHN 30, Tilwara-Nagpur Road, Manegaon, Jabalpur, MP, 482051.

## ABSTRACT

Diabetes mellitus is a group of metabolic disorder characterized by a complete lack of insulin, a relative lack of insulin, or insulin resistance. In response to the need for better control of diabetes, several new classes' antidiabetic drugs were introduced. Miglitol is a second-generation-glycosidase inhibitor with a chemical structure of 1-desoxynojiromycin. It acts as a potent competitive inhibitor of the alfa glycosidase in the microvilli of the intestinal brush border. Miglitol has a short biological half-life (2 h) and its bioavailability is>90%. Moreover, the site of absorption of miglitol is in the intestine. Transfersomes are particularly optimized, ultradeformable (ultraflexible) lipid supramolecular aggregates, which are able to penetrate the mammalian skin intact. Transfersome is a type of carrier system which is capable of transdermal delivery of low as well as high molecular weight drugs. Transfersomes penetrate through the pores of stratum corneum which are smaller than its size and get into the underlying viable skin in intact form. The aim of the present study was to investigate the potential of transfersomal gel formulations for transdermal delivery of Miglitol and to evaluate the effect of lipid concentration, ethanol concentration, drug concentration and stirrer time. Characterization of transfersomes performed by vesicle size, surface charge, entrapment efficiency and stability study. Characterization of transfersomes containing gel performed by the measurement of viscosity, pH measurements, drug content, extrudability study, spreadability and in vitro drug diffusion study. It was found that viscosity of prepared gel MG-12 was 3350cps, % assay was 99.45±0.45, extrudability was 147g and spreadability (g.cm/sec) was found that 13.25(g.cm/sec) respectively. *In vitro* drug release from transfersomes gel was carried out using Franz diffusion cell method and found 92.23% in 12 hr. In first 30 min it was 23.36 % drug release which slightly high. It was due to the release of free drug present in bag after leaching from transfersomes. Drug release from transferosomal gel formulation was found in very sustained and controlled manner. The prepared gel containing miglitol-loaded transfersomal formulation was optimized and can be use for topical preparation for its antidiabetic affect. The results were obtained which showed that transfersomal gel was a promising candidate for transdermal delivery with targeted and prolonged release of a drug. It also enhances skin permeation of many drugs.

**KEYWORDS:** Diabetes mellitus, Miglitol, Transfersomal gel, Franz diffusion cell, Characterization.

## INTRODUCTION

Diabetes mellitus is a chronic metabolic disorder that affects approximately 25% of population in the world and afflicts 150 million people and is set to rise to 300million by 2025.[1] In response to the need for better control of diabetes, several new classes' antidiabetic drugs were introduced in 1990s. Among these are Alpha Glucosidase Inhibitors such as Acarabose, Voglibose and Miglitol. These drugs having high affinity for the enzyme alpha glycosidase. A carbohydrate comprises of starch and sucrose are metabolized by this alpha glucosidase enzymes into monosaccharides in the small intestine before they are absorbed. This leads to delay in carbohydrate metabolism, prolongation of digestion time, and reduction in the rate of glucose absorption, finally resulting in inhibition of the rise of postprandial glucose levels.[2] The biological half-life of Miglitol is 2hrs and by conventional dosage form it requires oral administration of three times daily (TID). Transfersomes

are flexible or deformable vesicles and hence also called as elastic vesicles. Gregor Cevc in 1991 introduced the concept and term of elastic vesicles. Since then, extensive work is going on worldwide on these elastic vesicles under different titles like flexible vesicles, ethosomes", etc. Transfersome is derived from the Latin word 'transferre', meaning „to carry across", and the Greek word „soma", meaning „body". A transfersome carrier is an artificial vesicle that resembles the natural cell vesicle. Thus it is suitable for both targeted and controlled drug delivery. Functionally, it may be described as lipid droplet with such deformability that permits its easy penetration through the pores much smaller than the droplet size. Transfersome is a highly adaptable and stress-responsive complex aggregate. On topical application, the carrier search and exploits hydrophilic pathways i.e. 'pores' in the skin, which it opens wide enough to permit it to pass through with its drug cargo, deforming itself to accomplish this without losing its vesicular integrity. The vesicle is both self-regulating and self-optimizing due to its interdependency on local composition and shape of the bilayer. This allows the transfersome to cross different transport barriers efficiently. Transfersome penetrates the stratum corneum either via intracellular route or the transcellular route.[3,4] Transfersome has unique feature to provide improved permeation through skin due to its physico-structural properties. Liposomal as well as niosomal systems, are not suitable for transdermal delivery, because of their poor skin permeability, breaking of vesicles, leakage of drug, aggregation, and fusion of vesicles.[5,6] To address above mentioned problems, a new type of carrier system called transfersome has recently been introduced, which is capable of delivering low as well as high molecular weight drugs across the skin.

## MATERIALS AND METHODS

### Materials

Miglitol and Soya PC were purchased from Himedia Laboratory, Mumbai. Ethanol, chloroform and carbopol-934 purchased from CDH chemical Pvt. Ltd. New Delhi. Dialysis membrane of Mol Wt cutoff 1200 was purchased from Himedia Laboratory, Mumbai. Demineralized and double distilled water was prepared freshly and used whenever required. All other reagents and chemicals used were of analytical grade.

### Determination of $\lambda_{max}$ of Miglitol

Accurately weighed 10 mg of drug was dissolved in 10 ml of 7.4 pH buffer solution in 10 ml of volumetric flask. The resulted solution 1000µg/ml and from this solution 1 ml pipette out and transfer into 10 ml volumetric flask and volume make up with 7.4 pH buffer solution. Prepare suitable dilution to make it to a concentration range of 5-25µg/ml. The spectrum of this solution was run in 200-400 nm range in U.V. spectrophotometer (Labindia-3000+). A graph of concentration Vs absorbance was plotted.

### Preparation of miglitol-loaded transfersomes

Soya PC (0.5, 1.0, 1.5, 2.0% w/v) was dissolved in ethanol (5-25% v/v) and heated up to 30±1°C in a water bath in a closed vessel.[7] Distilled water or drug solution in distilled water (1% w/v solution), which is previously heated up to 30±1°C, was added slowly in a fine stream to the above ethanolic lipid solution with continuous mixing using a magnetic stirrer at 900 rpm. Mixing was continued for another 5 minutes and finally, the vesicular dispersions resulted was left to cool at room temperature (25±1°C) for 45 minutes.

### Optimization of transfersomes formulation

Transfersomes formulation optimized based on the evaluation of mentioned strategy procedure resting on the source of average vesicle size and (%) entrapment efficiency (EE). In the transfersomal formulation, the ratio of lipid was optimized by taking their different ratio such as 0.5, 1.0, 1.5, and 2.0% w/v ratio and all other parameters were kept remain constant. the ethanol content was optimized by taking their different quantity such as 5, 10, 15, and 20 and all other parameters were kept remain constant. Drug concentration optimized by taking different concentration of drug such as 1, 1.5, and 2.0% w/v and prepared their formulation and all other parameters such as Soya PC, stirrer time kept remain constant. Stirrer time was optimized by stirring the formulation for different time, i.e., 5, 10, and 15 min.

### Characterization of miglitol-loaded transfersomes

#### *Microscopic observation of prepared transferosomes*

An optical microscope (cippon, Japan) with a camera attachment (Minolta) was used to observe the shape of the prepared transferosomes formulation.

#### *Surface charge and vesicle size*

The vesicles size and size distribution and surface charge were determined by Dynamic Light Scattering method (DLS) (Malvern Zetamaster, ZEM 5002, Malvern, UK).

#### *Zeta potential*

The zeta potential was calculated according to Helmholtz–Smoluchowsky from their electrophoretic mobility. For measurement of zeta potential, a zetasizer was used with field strength of 20 V/cm on a large bore measures cell. Samples were diluted with 0.9% NaCl adjusted to a conductivity of 50 lS/cm.

#### *Entrapment efficiency*

Entrapment efficiency was determined by measuring the concentration of unentrapped free drug in aqueous medium. About 1 ml of the drug loaded transfersomes dispersion was placed in the Ependorf tubes and centrifuged at 17000 rpm for 30 min. The transfersomes along with encapsulated drug were separated at the bottom of the tubes. Plain transfersomes without drug was used as blank sample and centrifuged in the same manner. In order to measure the free drug concentration, the UV absorbance of the supernatant was determined at 269 nm.

***Stability studies***

Stability study was done for drug-loaded transfersomes at two different temperatures, i.e. refrigeration temperature (4.0 ± 0.2°C) and at room temperature (25–28 ± 2°C) for 3 months. The formulation subjected for stability study was put away in borosilicate compartment to maintain a strategic distance from any interface among the formulation and glass of container. The formulations were investigated for any physical changes and drug content.

**Preparation of gel base carbopol**

Carbopol 934 (1%w/v) was accurately weighed and dispersed into double distilled water (80ml) in a beaker. This solution was stirred continuously at 800 rpm for 1 hour and then 10ml of propylene glycol was added to this solution. Volume of gel was adjusted to 100 ml and then sonicated for 10 min on bath sonicator to remove air bubbles. Final pH of the gel base was adjusted to 6.5. Transferosomal preparation corresponding to 2% w/w of miglitol was incorporated into the gel base to get the desired concentration of drug in gel base.

**Characterization of transfersomes containing gel**

***Measurement of viscosity***

Viscosity measurements of prepared topical transfersomes based gel were measured by Brookfield viscometer using spindle no. 63 with the optimum speed of 10 rpm.

***pH measurements***

The pH of selected optimized formulations was established with the help of digital pH meter. The pH meter was calibrated with the help of buffer solution of pH 4, pH 7 and pH 9. After calibration, the electrode was dipped into the vesicles. Then, pH of selected formulation was measured and readings shown on display were noted.

***Drug content***

Accurately weighed 100 mg of topical transferosomal gel was taken in beaker and added 20 ml of methanol. This solution was mixed thoroughly and filtered by means of Whatman filter paper No. 1. Then, 1.0 ml of filtered solution was engaged in 10 ml capacity of volumetric flask; moreover, volume was ready up to 10 ml by means of methanol. This solution was analyzed using UV spectrophotometer at λmax 269 nm.

***Extrudability study***

Extrudability was determined on the amount of the gel extruded as of collapsible tube on appliance of certain load. More the quantity of gel extruded shows better extrudability. It was determined by applying the weight on gel filled collapsible tube and recorded the weight on which gel was extruded from tube.

***Spreadability***

Spreadability of formulation is necessary to provide sufficient dose available to absorb from skin to get good therapeutic response. An apparatus in which a slide fixed on wooden block and upper slide has movable and one end of movable slide tied with weight pan. To determine spreadability, 2-5 gm of gel placed between two slides and gradually weight was increased by adding it on the weight pan and time required with the top plate to face the distance of 10 cm on adding 80 g of weight was noted. Good spreadability shows lesser time to spread. It is determine by formula given below.[8]

$$s = \frac{m * l}{t}$$

Where, S=Spreadability (gcm/sec), m = weight tied to the upper slide (20 grams),

l= length of glass slide (6cms), t = time taken is seconds.

***In vitro drug diffusion study***

The in vitro diffusion study about is conveyed by utilizing Franz diffusion cell. Egg membrane is taken as semi penetrable membrane for diffusion.[9] The Franz diffusion cell has receptor compartment with an effective volume roughly 60 ml and compelling surface area of permeation 3.14sq.cm. The egg membrane is placed between the donor and the receptor compartment. A $2cm^2$ size patch taken and weighed then set on one face of membrane confronting donor compartment. The receptor medium is phosphate buffer pH 7.4. The receptor compartment is encompassed through water casing to keep up the temperature at 32 ± 0.5°C. Warmth is furnished utilizing a thermostatic hot plate with a magnetic stirrer. The receptor liquid is mixed by Teflon covered magnetic bead which is put in the diffusion cell. Amid each testing interim, samples are pulled back and replaced by equivalent volumes of fresh receptor liquid on each sampling. The samples withdrawn are analyzed spectrophotometrically at wavelength of drug 269 nm.

**RESULTS AND DISCUSSIONS**

The absorption maxima of miglitol were determined by running the spectrum of drug solution in double beam ultraviolet spectrophotometer (Labindia UV 3000+) using concentration range of 5-25µg/ml miglitol in 7.4phosphate buffers. Miglitol showed a linear relationship with correlation coefficient of 0.9998 in the concentration range of 5-25µg/ml in phosphate buffer pH 7.4. Melting point of drug was found 112-116°C while it was 114°C reported in standard monograph. All the data of preformulation study were found similar as given in standard monograph which confirmed that the drug was authenticated and pure in form and it could be used for formulation development of miglitol-loaded transfersomes.

Optimization of the transfersomes to generate the formulation code was done using the strategy as reflected in Table 1 optimization of lipid concentration, Table 2 optimization of ethanol concentration, Table 3 optimization of drug concentration and Table 4 optimization of stirrer time. It was observed that the vesicles dimension of transfersomes was increased with raising the concentration of phosphatidylcholine and

ethanol. There was no noteworthy difference observed in average vesicle size with increasing the drug concentration, but with increase in the stirrer time the size of vesicle decreased from 145.45to 125.65 after 15 min of stirring. Considering the EE, it was observed that the percent drug entrapment decreased with escalating the concentration of ethanol and on escalating the time of stirring. It is due to the leaching out the drug from vesicles on increasing the mechanical force by stirrer and size reduction of transfersomes on increasing the concentration of ethanol. It was clearly shown when formulation was stirred for 5, 10, and 15 min then the % EE was 78.25, 63.32, and 60.23. 5 minis selected as optimized time for stirrer because it provided the required size of vesicle 133.12 nm and good % EE, i.e., 78.25. The resulted formulation code F-12 was considered as the optimized formulation. The average vesicle size of optimized formulation (F-12) observed as 133.12 nm, zeta potential observed as -32.4mV and %EE was found as 78.25%. Stability study was performed on optimized formulation (F-12) and its characterization depicted in Table 5. Stability study data revealed that the optimized formulation (F-12) was stable after 3 months of storage at 4.0°C ± 0. 2°C while at 25-28±2°C, the formulation was found unstable. Stability of formulation was observed on the basis of % drug remain, average vesicles size and physical appearance. Prepared gel of transfersomes loaded with miglitol (MG-12) was prepared and evaluated for viscosity, pH, % drug content, extrudability, spreadability and drug release study. It was found that viscosity of prepared gel MG-12 was 3350cps, % assay was 99.45±0.45, extrudability was 147g and spreadability (g.cm/sec) was found that 13.25(g.cm/sec) respectively. *In vitro* drug release (Table 6 & Figure 1) from transfersomes gel was carried out using Franz diffusion cell method and found 92.23% in 12 hr. In first 30 min it was 23.36 % drug release which slightly high. It was due to the release of free drug present in bag after leaching from transfersomes. Drug release from transferosomal gel formulation was found in very sustained and controlled manner.

**Table 1: Optimization of lipid concentration.**

| F. code | Soya PC (% w/v) | Ethanol | Drug (% w/v) | Average vesicle size (nm) | % entrapment efficiency |
|---|---|---|---|---|---|
| F1 | 0.5 | 10 | 1.0 | 325.32 | 69.98 |
| **F2** | **1.0** | **10** | **1.0** | **275.56** | **72.56** |
| F3 | 1.5 | 10 | 1.0 | 245.56 | 65.23 |
| F4 | 2.0 | 10 | 1.0 | 233.23 | 48.89 |

**Table 2: Optimization of ethanol concentration.**

| F. code | Soya PC (% w/v) | Ethanol | Drug (% w/v) | Average vesicle size (nm) | % entrapment efficiency |
|---|---|---|---|---|---|
| F5 | 1.0 | 5 | 1.0 | 289.85 | 68.89 |
| **F6** | **1.0** | **10** | **1.0** | **210.23** | **73.32** |
| F7 | 1.0 | 15 | 1.0 | 263.32 | 63.32 |
| F8 | 1.0 | 20 | 1.0 | 252.12 | 64.47 |

**Table 3: Optimization of drug concentration.**

| F. code | Soya PC (% w/v) | Drug (% w/v) | Ethanol (ml) | Average vesicle size (nm) | % Entrapment efficiency |
|---|---|---|---|---|---|
| **F9** | **1.0** | **1.0** | **10** | **245.56** | **78.25** |
| F10 | 1.0 | 1.5 | 10 | 265.23 | 65.23 |
| F11 | 1.0 | 2.0 | 10 | 230.45 | 45.58 |

**Table 4: Optimization of stirrer time.**

| F. code | Soya PC: (% w/v) | Drug (% w/v) | Stirrer time (min) | Average vesicle size (nm) | % Entrapment efficiency |
|---|---|---|---|---|---|
| **F12** | **1.0** | **1.0** | **5** | **133.12** | **78.25** |
| F13 | 1.0 | 1.0 | 10 | 145.45 | 63.32 |
| F14 | 1.0 | 1.0 | 15 | 125.65 | 60.23 |

**Table 5: Characterization of optimized formulation of transfersomes formulation.**

| Characteristic | Time (Month) | | | | | |
|---|---|---|---|---|---|---|
| | 1 Month | | 2 Month | | 3 Month | |
| **Temperature** | **4.0 ±0. 2°C** | **25-28±2°C** | **4.0 ±0. 2°C** | **25-28±2°C** | **4.0 ±0. 2°C** | **25-28±2°C** |
| **Average particle size (nm)** | 133.12 | 145.25 | 130.14 | 205.45 | 142.23 | 236.65 |
| **% EE** | 78.25 | 69.98 | 70.23 | 55.52 | 69.32 | 50.32 |
| **Physical Appearance** | Normal | Turbid | Normal | High turbid | Normal | High turbid |

**Table 6: *In vitro* drug release study of prepared gel formulation.**

| S. No. | Time (hr) | % Cumulative Drug Release |
|---|---|---|
| 1 | 0.5 | 23.36 |
| 2 | 1 | 39.98 |
| 3 | 2 | 46.65 |
| 4 | 4 | 55.52 |
| 5 | 6 | 69.98 |
| 6 | 8 | 73.32 |
| 7 | 12 | 92.23 |




**Figure 1: *In vitro* drug release of gel based transferosomal gel.**

## CONCLUSION

Transfersomes were prepared and optimized on the base of average vesicle size and % drug entrapment. The optimized formulation was further incorporated with gel base (Carbopol gel) and characterized for their viscosity, pH, % drug content, extrudability, spreadability and drug release study. Optimized formulation (F-12) of transfersomes resulted in average vesicle size as 133.12 nm, zeta potential as -32.4mV and % EE as 78.25% and stability study data revealed that the optimized formulation was stable after 3 months of storage at 4.0° ±0.2°C. Prepared gel of optimized formulation viscosity was 3350cps, % drug content was 99.45±0.45, extrudability was 147g, spreadability (g.cm/sec) was 13.25 (g.cm/sec) and in vitro drug release found as 92.23 % in 12 h, respectively. It can be concluded that prepared gel containing miglitol-loaded transfersomal formulation was optimized and can be of use for topical preparation for its antidiabetic effect.

## REFERENCES

1. Vats RK, Kumar V, Kothari A, Mital A and Uma Rama-chandran, Emerging targets for diabetes. Curr Science, 2005; 88: 241-247.
2. Jean–Pierre JE sels, Maya SP Huijberts and Bruce HR Wolffenbutte, Miglitol, a new Alpha Glucosidase Inhibitor. Expert opinion on Pharmacotherapy, 1999; 1(1): 149-156.
3. Cevc G. Lipid vesicles and other colloids as drug carriers on the skin. Adv. Drug delivery Rev., 2004; 56(5): 675-711.
4. Sivannarayana P, Prameela Rani A, Saikishore V. tr ansferosomes: Ultra Deformable Vesicular Carrier Systems in Transdermal Drug Delivery System, Research J. Pharma. Dosage Forms and Tech., 2012; 4(5): 243-255340-343.
5. M. Gulati, S. Bajad, S. Singh, A. J. Ferdous, and M. Singh, Development of liposomal amphotericin B formulation. J. microencapsulation, 1998; 15: 137.
6. G. Cevc, G. Blume, and A. Schatzlein, Transfersomes-mediated transepidermal delivery improves the regio-specificity and biological activity of corticosteroids in vivo. J. Control. Rel., 1997; 45: 211.
7. Anish P. Thomas, Raghvendra Dubey, Prabhat Jain. Formulation and Evaluation of Ethosomal Gel of Tazarotene for Topical Delivery. Asian Journal of Pharmaceutics, 2019; 13(1): 38-45.
8. Nimker V, Jamal H, Gosh P, Jain S, Beotra A. Liposomes; drug delivery system or possible doping agent. J Drug Deliv Ther., 2017; 7: 25-9.
9. Zhaoa YZ, Zhanga Y, Xiaoa J, Zhaob YP, Tianc JL, Xud YY, et al. Selection of high efficient transdermal lipid vesicle for curcumin skin delivery. Int J Pharm., 2013; 454: 1-15.